Literature DB >> 10956319

RAS blockade: new possibilities in the treatment of complications of diabetes.

L Ruilope1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10956319      PMCID： PMC1766524          DOI： 10.1136/heart.84.suppl_1.i32

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


× No keyword cloud information.
  10 in total

1.  Long-term treatment with candesartan cilexetil does not affect glucose homeostasis or serum lipid profile in mild hypertensives with type II diabetes.

Authors:  P Trenkwalder; M Lehtovirta; K Dahl
Journal:  J Hum Hypertens       Date:  1997-09       Impact factor: 3.012

2.  Effects of an angiotensin II receptor antagonist, TCV-116, on renal haemodynamics in essential hypertension.

Authors:  M Kawabata; T Takabatake; H Ohta; S Nakamura; H Hara; K Ohta; H Takakuwa; W H Han; K Kobayashi
Journal:  Blood Press Suppl       Date:  1994

Review 3.  New hormonal blockade strategies in cardiovascular disease.

Authors:  C I Johnston; M Naitoh; J Risvanis; N Farina; L M Burrell
Journal:  Scand Cardiovasc J Suppl       Date:  1998

4.  The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.

Authors:  R A Rodby; R D Rohde; W R Clarke; L G Hunsicker; D A Anzalone; R C Atkins; E Ritz; E J Lewis
Journal:  Nephrol Dial Transplant       Date:  2000-04       Impact factor: 5.992

Review 5.  Renoprotection and renin-angiotensin system blockade in diabetes mellitus.

Authors:  L M Ruilope
Journal:  Am J Hypertens       Date:  1997-12       Impact factor: 2.689

6.  Renal sensitivity to angiotensin II in type 1 diabetes.

Authors:  S Björck; M Aurell; L E Bresäter; H Herlitz; L Welin; J Wikstrand
Journal:  Scand J Urol Nephrol       Date:  1990

7.  Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease.

Authors:  R T Gansevoort; D de Zeeuw; S Shahinfar; A Redfield; P E de Jong
Journal:  J Hypertens Suppl       Date:  1994-07

Review 8.  Renal circulation and blockade of the renin-angiotensin system. Is angiotensin-converting enzyme inhibition the last word?

Authors:  N K Hollenberg; N D Fisher
Journal:  Hypertension       Date:  1995-10       Impact factor: 10.190

Review 9.  Pathways for angiotensin II generation in intact human tissue: evidence from comparative pharmacological interruption of the renin system.

Authors:  N K Hollenberg; N D Fisher; D A Price
Journal:  Hypertension       Date:  1998-09       Impact factor: 10.190

10.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group.

Authors:  L Hansson; A Zanchetti; S G Carruthers; B Dahlöf; D Elmfeldt; S Julius; J Ménard; K H Rahn; H Wedel; S Westerling
Journal:  Lancet       Date:  1998-06-13       Impact factor: 79.321
  10 in total
  1 in total

Review 1.  Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.

Authors:  Katherine F Croom; Monique P Curran; Karen L Goa; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.